title: [Efficacy of DPP-4 inhibitor evaluated by CGM (continuous glucose monitoring)].
abstract: The primary treatment goal for patients with diabetes is to prevent the onset and progression of diabetic complications. To prevent cardiovascular events, patients must maintain optimal long-term glycemic control and avoid hypoglycemia. DPP-4 inhibition enhances endogenous incretin action, and promotes glucose dependent insulin secretion and optimal glucagon secretion. Thus, DPP-4 inhibitor can improve postprandial hyperglycemia, without causing hypoglycemia in patients with diabetes. In this section, a continuous glucose monitoring(CGM), a device able to measure a patient's blood glucose fluctuation levels continuously, was used to evaluate efficacy of DPP-4 inhibitors.
authors.affiliation: Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine.
authors.forename: Rimei
authors.initials: R
authors.lastname: Nishimura
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000517:prevention & control*; D054795:Incretins / Q000097:blood; D007328:Insulin / Q000097:blood
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D054795:Incretins; D007328:Insulin